Aquaporin-4–binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2

Neuromyelitis optica (NMO)-immunoglobulin G (IgG) is a clinically validated serum biomarker that distinguishes relapsing central nervous system (CNS) inflammatory demyelinating disorders related to NMO from multiple sclerosis. This autoantibody targets astrocytic aquaporin-4 (AQP4) water channels. Clinical, radiological, and immunopathological data suggest that NMO-IgG might be pathogenic. Characteristic CNS lesions exhibit selective depletion of AQP4, with and without associated myelin loss; focal vasculocentric deposits of IgG, IgM, and complement; prominent edema; and inflammation. The effect of NMO-IgG on astrocytes has not been studied. In this study, we demonstrate that exposure to NMO patient serum and active complement compromises the membrane integrity of CNS-derived astrocytes. Without complement, astrocytic membranes remain intact, but AQP4 is endocytosed with concomitant loss of Na+-dependent glutamate transport and loss of the excitatory amino acid transporter 2 (EAAT2) . Our data suggest that EAAT2 and AQP4 exist in astrocytic membranes as a macromolecular complex. Transport-competent EAAT2 protein is up-regulated in differentiating astrocyte progenitors and in nonneural cells expressing AQP4 transgenically. Marked reduction of EAAT2 in AQP4-deficient regions of NMO patient spinal cord lesions supports our immunocytochemical and immunoprecipitation data. Thus, binding of NMO-IgG to astrocytic AQP4 initiates several potentially neuropathogenic mechanisms: complement activation, AQP4 and EAAT2 down-regulation, and disruption of glutamate homeostasis.

[1]  Yasuto Itoyama,et al.  Preferential spinal central gray matter involvement in neuromyelitis optica , 2008, Journal of neurology.

[2]  J. Newcombe,et al.  Glutamate Receptor Expression in Multiple Sclerosis Lesions , 2008, Brain pathology.

[3]  C. Lucchinetti,et al.  Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica , 2007, Neurology.

[4]  B. Weinshenker,et al.  The spectrum of neuromyelitis optica , 2007, The Lancet Neurology.

[5]  J. Parisi,et al.  Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. , 2007, Brain : a journal of neurology.

[6]  G. Hu,et al.  Aquaporin-4 deficiency down-regulates glutamate uptake and GLT-1 expression in astrocytes , 2007, Molecular and Cellular Neuroscience.

[7]  R. Bridges,et al.  Regional Distribution of Sodium-Dependent Excitatory Amino Acid Transporters in Rat Spinal Cord , 2007, The journal of spinal cord medicine.

[8]  A. Pérez-Samartín,et al.  Activation of Kainate Receptors Sensitizes Oligodendrocytes to Complement Attack , 2006, The Journal of Neuroscience.

[9]  M. Salter,et al.  NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury , 2005, Nature.

[10]  A. Verkman,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[11]  A. A. Jensen,et al.  Pharmacological characterization of human excitatory amino acid transporters EAAT1, EAAT2 and EAAT3 in a fluorescence-based membrane potential assay. , 2004, Biochemical pharmacology.

[12]  J. Kemp,et al.  NMDA receptor pathways as drug targets , 2002, Nature Neuroscience.

[13]  H. Grossniklaus A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Luchinetti CF,∗ Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuck D, Parisi JE, Lassman H. Brain 2002;125:1450–1461 , 2002 .

[14]  Hans Lassmann,et al.  A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. , 2002, Brain : a journal of neurology.

[15]  N. Danbolt Glutamate uptake , 2001, Progress in Neurobiology.

[16]  A. Pérez-Samartín,et al.  The link between excitotoxic oligodendroglial death and demyelinating diseases , 2001, Trends in Neurosciences.

[17]  J. Rothstein,et al.  Modulation of the neuronal glutamate transporter EAAC1 by the interacting protein GTRAP3-18 , 2001, Nature.

[18]  D. Small,et al.  Developmental regulation of glutamate transporters and glutamine synthetase activity in astrocyte cultures differentiated in vitro , 1999, International Journal of Developmental Neuroscience.

[19]  J. Mcdonald,et al.  Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity , 1998, Nature Medicine.

[20]  P. Agre,et al.  Specialized Membrane Domains for Water Transport in Glial Cells: High-Resolution Immunogold Cytochemistry of Aquaporin-4 in Rat Brain , 1997, The Journal of Neuroscience.

[21]  P. Gasque,et al.  Expression of complement in the brain: role in health and disease. , 1996, Immunology today.

[22]  J. Storm-Mathisen,et al.  Glutamate transporters in glial plasma membranes: Highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry , 1995, Neuron.

[23]  M. Robinson,et al.  Pharmacology of Sodium‐Dependent High‐Affinity l‐[3H]Glutamate Transport in Glial Cultures , 1995, Journal of neurochemistry.

[24]  J. Storm-Mathisen,et al.  An [Na+ + K+]coupledl-glutamate transporter purified from rat brain is located in glial cell processes , 1992, Neuroscience.

[25]  D. Muir,et al.  CG‐4, A new bipotential glial cell line from rat brain, is capable of differentiating in vitro into either mature oligodendrocytes or type‐2 astrocytes , 1992, Journal of neuroscience research.

[26]  Patrick Vermersch,et al.  Neuromyelitis optica and non organ-specific autoimmunity. , 2008, Archives of neurology.

[27]  M. Nakamura M. D.,et al.  Preferential spinal central gray matter involvement in neuromyelitis optica , 2008, Journal of Neurology.

[28]  H. Wiśniewski,et al.  The distribution of Ia antigen in the lesions of rat acute experimental allergic encephalomyelitis , 2004, Acta Neuropathologica.

[29]  D. Pitt,et al.  Glutamate excitotoxicity in a model of multiple sclerosis , 2000, Nature Medicine.

[30]  L. Turski,et al.  Autoimmune encephalomyelitis ameliorated by AMPA antagonists , 2000, Nature Medicine.

[31]  C. Matute,et al.  On how altered glutamate homeostasis may contribute to demyelinating diseases of the CNS. , 1999, Advances in experimental medicine and biology.